Release Summary

Juno and Celgene's JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Juno Therapeutics, Inc.